<?xml version="1.0" encoding="UTF-8"?>
<p>In parallel to the JIKI trial, and anticipating the limitations due to the study design, in particular the absence of a control group, nonhuman primate (NHP) studies were planned to optimize the use of favipiravir for subsequent trials. In these experiments, the first objective was to characterize favipiravir PKs and to use modeling techniques to identify relevant dosing regimens and drug concentrations.</p>
